Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

29.84B

Market cap29.84B

Price-Earnings ratio

22.42

Price-Earnings ratio22.42

Dividend yield

—

Dividend yield—

Average volume

1.38M

Average volume1.38M

High today

$204.25

High today$204.25

Low today

$199.40

Low today$199.40

Open price

$201.32

Open price$201.32

Volume

417.03K

Volume417.03K

52 Week high

$219.72

52 Week high$219.72

52 Week low

$124.56

52 Week low$124.56

Stock Snapshot

With a market cap of 29.84B, Biogen(BIIB) trades at $202.14. The stock has a price-to-earnings ratio of 22.42.

On 2026-07-28, Biogen(BIIB) stock traded between a low of $199.40 and a high of $204.25. Shares are currently priced at $202.14, which is +1.4% above the low and -1.0% below the high.

Biogen(BIIB) shares are trading with a volume of 417.03K, against a daily average of 1.38M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $124.56.

BIIB News

MarketWatch 20h

Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch

...

Nasdaq 1d

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

The second-quarter 2024 reporting cycle of the Medical sector will gain further traction this week. The sector mainly comprises pharma/biotech and medical devic...

TipRanks 1d

Biogen’s BIIB144 First‑in‑Human Trial: What Early Safety Data Could Mean for BIIB Investors

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Analyst ratings

61%

of 36 ratings

Buy

61.1%

Hold

33.3%

Sell

5.6%

More BIIB News

Simply Wall St 5d

At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen

Eisai and Biogen recently gained US FDA approval for LEQEMBI IQLIK, an at-home subcutaneous autoinjector for early Alzheimer’s treatment initiation and maintena...

Investor's Business Daily 6d

Why Arrowhead Shot Sky-High, While Its Chief Rival, Ionis, Toppled

Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers' 7/14/2026 Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowe...

TipRanks 7d

Biogen: Balanced Risk-Reward Keeps Rating at Hold Amid MS Pressure and Uncertain New Asset Contributions

Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Biogen today and set a price target of $215.00. Claim 55% Off TipRanks Unlock powe...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.